Experts discuss two cases on first-line management of advanced non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs).
This activity is intended for hematologists/oncologists, pulmonologists, pathologists, and nurses.
Approximate Time to Complete: 30 minutes
Credit Available: Nov. 26, 2018- Nov. 26, 2019
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding clinical trial data on the use of ICIs alone or in combination in first-line management of advanced NSCLC
- Have greater competence related to identifying patients with advanced NSCLC who may benefit from the use of ICIs
- Have greater competence related to management of irAEs in patients with advanced NSCLC